Skip Nav Destination
Issues
1 July 2011
-
Cover Image
Cover Image
A novel TRIM family member TRIM59 has proto-oncogenic activity in a transgenic mouse prostate cancer modeling test. Restricted TRIM59 gene expression in the mouse prostate using a prostate tissue-specific gene (PSP94) revealed the full potential for tumorigenesis and developed poorly differentiated cancer of the prostate and comedocarcinoma, which had features of neurocarcinoma (small cell carcinoma) and central necrosis. The PSP94-TRIM59 mice coincided with the upregulation of genes specific to the Ras signaling pathway and bridging genes for SV40Tag-mediated oncogenesis. For details, see the article by Valiyeva and colleagues on page 1229. - PDF Icon PDF LinkTable of Contents
ISSN 1535-7163
EISSN 1538-8514
Highlights
Review
Novel Therapeutic Options in Anaplastic Large Cell Lymphoma: Molecular Targets and Immunological Tools
Olaf Merkel; Frank Hamacher; Eveline Sifft; Lukas Kenner; Richard Greil; for the European Research Initiative on Anaplastic Large Cell Lymphoma
Therapeutic Discovery
Preclinical Development
Response of Human Prostate Cancer Cells and Tumors to Combining PARP Inhibition with Ionizing Radiation
Juan Camilo Barreto-Andrade; Elena V. Efimova; Helena J. Mauceri; Michael A. Beckett; Harold G. Sutton; Thomas E. Darga; Everett E. Vokes; Mitchell C. Posner; Stephen J. Kron; Ralph R. Weichselbaum
Pharmacodynamic Evaluation of the Target Efficacy of SB939, an Oral HDAC Inhibitor with Selectivity for Tumor Tissue
Veronica Novotny-Diermayr; Nina Sausgruber; Yung Kiang Loh; Mohammed Khalid Pasha; Ramesh Jayaraman; Hannes Hentze; Wei-Peng Yong; Boon-Cher Goh; Han-Chong Toh; Kantharaj Ethirajulu; Joy Zhu; Jeanette Marjorie Wood
E7080 Suppresses Hematogenous Multiple Organ Metastases of Lung Cancer Cells with Nonmutated Epidermal Growth Factor Receptor
Hirokazu Ogino; Masaki Hanibuchi; Soji Kakiuchi; Van The Trung; Hisatsugu Goto; Kenji Ikuta; Tadaaki Yamada; Hisanori Uehara; Akihiko Tsuruoka; Toshimitsu Uenaka; Wei Wang; Qi Li; Shinji Takeuchi; Seiji Yano; Yasuhiko Nishioka; Saburo Sone
Novel Acrylonitrile Derivatives, YHO-13177 and YHO-13351, Reverse BCRP/ABCG2-Mediated Drug Resistance In Vitro and In Vivo
Ryuta Yamazaki; Yukiko Nishiyama; Tomio Furuta; Hiroshi Hatano; Yoshiaki Igarashi; Naoyuki Asakawa; Hiroshi Kodaira; Hiroyuki Takahashi; Ritsuo Aiyama; Takeshi Matsuzaki; Nao Yagi; Yoshikazu Sugimoto
Molecular Medicine in Practice
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.
RSS Feeds